Marcela F Pasetti

Grant Detail

The grant detail shows the name of the PI, active dates of the project, the funding institute and the abstract of the grant. This abstract is what is used to create the fingerprint of the grant. If any publications referencing this grant are found in the data, they will be listed here as well.

ENTERIC DISEASES VACCINE EVALUATION & TREATMENT UNIT

Myron M Levine

19 Resulting Publications

• 1.

  1998

  M S Donnenberg; C O Tacket; G Losonsky; G Frankel; J P Nataro; G Dougan; M M Levine

  Effect of prior experimental human enteropathogenic Escherichia coli infection on illness following homologous and heterologous rechallenge.

  Infection and immunity 1998;66(1):52-8.

• 2.

  1997

  C O Tacket; S M Kelly; F Schödel; G Losonsky; J P Nataro; R Edelman; M M Levine; R Curtiss

  Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system.

  Infection and immunity 1997;65(8):3381-5.

• 3.

  1997

  J E Galen; O G Gomez-Duarte; G A Losonsky; J L Halpern; C S Lauderbaugh; S Kaintuck; M K Reymann; M M Levine

  A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens.

  Vaccine 1997;15(6-7):700-8.

• 4.

  1996

  J G Morris; M B Sztein; E W Rice; J P Nataro; G A Losonsky; P Panigrahi; C O Tacket; J A Johnson

  Vibrio cholerae O1 can assume a chlorine-resistant rugose survival form that is virulent for humans.

  The Journal of infectious diseases 1996;174(6):1364-8.

• 5.

  1996

  E M Barry; O Gomez-Duarte; S Chatfield; R Rappuoli; M Pizza; G Losonsky; J Galen; M M Levine

  Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908.

  Infection and immunity 1996;64(10):4172-81.

• 6.

  1996

  G A Losonsky; J Yunyongying; V Lim; M Reymann; Y L Lim; S S Wasserman; M M Levine

  Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera.

  Infection and immunity 1996;64(1):10-5.

• 7.

  1995

  O G Gómez-Duarte; J Galen; S N Chatfield; R Rappuoli; L Eidels; M M Levine

  Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain.

  Vaccine 1995;13(16):1596-602.

• 8.

  1995

  C O Tacket; G Losonsky; J P Nataro; L Comstock; J Michalski; R Edelman; J B Kaper; M M Levine

  Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge.

  The Journal of infectious diseases 1995;172(3):883-6.

• 9.

  1995

  R Lagos; A Avendaño; V Prado; I Horwitz; S Wasserman; G Losonsky; S Cryz; J B Kaper; M M Levine

  Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O.

  Infection and immunity 1995;63(2):707-9.

• 10.

  1995

  J P Nataro; Y Deng; S Cookson; A Cravioto; S J Savarino; L D Guers; M M Levine; C O Tacket

  Heterogeneity of enteroaggregative Escherichia coli virulence demonstrated in volunteers.

  The Journal of infectious diseases 1995;171(2):465-8.

• 11.

  1995

  J B Kaper; J G Morris; M M Levine

  Cholera.

  Clinical microbiology reviews 1995;8(1):48-86.

• 12.

  1994

  M B Sztein; S S Wasserman; C O Tacket; R Edelman; D Hone; A A Lindberg; M M Levine

  Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi.

  The Journal of infectious diseases 1994;170(6):1508-17.

• 13.

  1994

  S S Wasserman; G A Losonsky; F Noriega; C O Tacket; E Castañeda; M M Levine

  Kinetics of the vibriocidal antibody response to live oral cholera vaccines.

  Vaccine 1994;12(11):1000-3.

• 14.

  1994

  C Gonzalez; D Hone; F R Noriega; C O Tacket; J R Davis; G Losonsky; J P Nataro; S Hoffman; A Malik; E Nardin; et al.

  Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans.

  The Journal of infectious diseases 1994;169(4):927-31.

• 15.

  1993

  C O Tacket; G Losonsky; J P Nataro; S J Cryz; R Edelman; A Fasano; J Michalski; J B Kaper; M M Levine

  Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae.

  The Journal of infectious diseases 1993;168(6):1536-40.

• 16.

  1993

  M S Donnenberg; C O Tacket; S P James; G Losonsky; J P Nataro; S S Wasserman; J B Kaper; M M Levine

  Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection.

  The Journal of clinical investigation 1993;92(3):1412-7.

• 17.

  1992

  C O Tacket; G Losonsky; J P Nataro; S J Cryz; R Edelman; J B Kaper; M M Levine

  Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR.

  The Journal of infectious diseases 1992;166(4):837-41.

• 18.

  1992

  J P Nataro; Y Deng; D R Maneval; A L German; W C Martin; M M Levine

  Aggregative adherence fimbriae I of enteroaggregative Escherichia coli mediate adherence to HEp-2 cells and hemagglutination of human erythrocytes.

  Infection and immunity 1992;60(6):2297-304.

• 19.

  1992

  C O Tacket; D M Hone; R Curtiss; S M Kelly; G Losonsky; L Guers; A M Harris; R Edelman; M M Levine

  Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers.

  Infection and immunity 1992;60(2):536-41.

Scientific Context

This section shows information that has been computed by using the fingerprint of the grant, including related publications, related experts and related grants - all with fingerprints representing significant amounts of overlap between their fingerprint and this grant. The red dots indicate whether those experts or terms actually appear within this grant, showing potential and actual connections.